Silver Book Fact

For beneficiaries with wet age-related macular degeneration (AMD), annual Medicare part B payments for vision care increased from $1,504 per beneficiary in 1994 to $3,263 in 2006–due in large part to anti-VEGF treatments.

Day, Shelley, Kofi Acquah, Paul P. Lee, Prithvi Mruthyunjaya, and Frank A. Sloan. Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007. Ophthalmol. May 2011; 152(6): 1014-20. http://www.ajo.com/article/S0002-9394%2811%2900410-7/abstract

Reference

Title
Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007
Publication
Ophthalmol
Publication Date
May 2011
Authors
Day, Shelley, Kofi Acquah, Paul P. Lee, Prithvi Mruthyunjaya, and Frank A. Sloan
Volume & Issue
Volume 152, Issue 6
Pages
1014-20
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • The cost of lost productivity due to dry eye is estimated at more than $5,000 per patient.  
  • An estimated 6.5% of Americans age 40 and older have age-related macular degeneration (AMD).  
  • Number of Patients Aged 40 to 64 Using Medical Services, Medications and Vitamins  
  • More than 1 million Americans ages 40-49 are estimated to have diabetic retinopathy. That grows to close to 2 million at ages 65-74.  
  • An individual who is visually impaired or blind accumulates nearly $1,479 in vision-related expenses each year– not including health utility or QALY losses. At this rate, after 8 years an…